1. Home
  2. INDP vs AEI Comparison

INDP vs AEI Comparison

Compare INDP & AEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INDP
  • AEI
  • Stock Information
  • Founded
  • INDP 2000
  • AEI 2014
  • Country
  • INDP United States
  • AEI United States
  • Employees
  • INDP N/A
  • AEI N/A
  • Industry
  • INDP Biotechnology: Pharmaceutical Preparations
  • AEI Building operators
  • Sector
  • INDP Health Care
  • AEI Real Estate
  • Exchange
  • INDP Nasdaq
  • AEI Nasdaq
  • Market Cap
  • INDP 15.4M
  • AEI 13.4M
  • IPO Year
  • INDP N/A
  • AEI N/A
  • Fundamental
  • Price
  • INDP $1.11
  • AEI $1.47
  • Analyst Decision
  • INDP Strong Buy
  • AEI
  • Analyst Count
  • INDP 1
  • AEI 0
  • Target Price
  • INDP $12.00
  • AEI N/A
  • AVG Volume (30 Days)
  • INDP 20.2K
  • AEI 69.5K
  • Earning Date
  • INDP 11-04-2024
  • AEI 11-12-2024
  • Dividend Yield
  • INDP N/A
  • AEI N/A
  • EPS Growth
  • INDP N/A
  • AEI N/A
  • EPS
  • INDP N/A
  • AEI N/A
  • Revenue
  • INDP N/A
  • AEI $9,220,976.00
  • Revenue This Year
  • INDP N/A
  • AEI N/A
  • Revenue Next Year
  • INDP N/A
  • AEI N/A
  • P/E Ratio
  • INDP N/A
  • AEI N/A
  • Revenue Growth
  • INDP N/A
  • AEI N/A
  • 52 Week Low
  • INDP $1.03
  • AEI $0.46
  • 52 Week High
  • INDP $3.25
  • AEI $2.05
  • Technical
  • Relative Strength Index (RSI)
  • INDP 34.05
  • AEI 54.96
  • Support Level
  • INDP $1.10
  • AEI $1.39
  • Resistance Level
  • INDP $1.22
  • AEI $1.73
  • Average True Range (ATR)
  • INDP 0.12
  • AEI 0.22
  • MACD
  • INDP 0.00
  • AEI 0.03
  • Stochastic Oscillator
  • INDP 16.20
  • AEI 59.65

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.

About AEI Alset Inc. (TX)

Alset Inc is a diversified holding company engaged through its subsidiaries in the development of EHome communities and other real estate, financial services, digital transformation technologies, biohealth activities, and consumer products with operations in the United States, Singapore, Hong Kong, Australia, and South Korea. The Company operates in four business segments: real estate, digital transformation technology, Biohealth, and other business activities, and it derives a majority of its revenue from the Real Estate segment.

Share on Social Networks: